Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 13/20 | 1.00 |
| ▸ | CA12 | O43570 | 5/20 | 1.00 |
| ▸ | MARS1 | P56192 | 1/20 | 0.76 |
| ▸ | TP53 | P04637 | 2/20 | 0.72 |
| ▸ | RPA1 | P27694 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | CA9 | Q16790 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2846632 | 0.85 | ALPL (0.73) | ALPLCA12MARS1TP53RPA1 | |
| SCHEMBL13539283 | 0.85 | ALPL (0.73) | ALPLCA12MARS1TP53RPA1 | |
| SCHEMBL2658851 | 0.84 | ALPL (0.73) | ALPLCA12MARS1TP53RPA1 | |
| SCHEMBL1414100 | 0.84 | ALPL (1.00) | ALPLCA12MARS1TP53RPA1 | |
| SCHEMBL726574 | 0.84 | TP53 (1.00) | ALPLCA12TP53RPA1CA9 | |
| SCHEMBL2558820 | 0.83 | ALPL (0.71) | ALPLCA12MARS1TP53RPA1 | |
| SCHEMBL29732894 | 0.83 | ALPL (0.71) | ALPLCA12MARS1TP53RPA1 | |
| SCHEMBL16701162 | 0.83 | ALPL (0.70) | ALPLCA12MARS1TP53RPA1 | |
| SCHEMBL23803931 | 0.83 | ALPL (0.73) | ALPLCA12MARS1TP53RPA1 | |
| SCHEMBL3447352 | 0.83 | ALPL (1.00) | ALPLCA12MARS1TP53RPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164329-A2 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | The Burnham Institute for Medical Research (US) | 2010-03-24 | — | — | EP | claimed |
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-06-18 | — | — | US | claimed |
| WO-2009017863-A2 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-05 | — | — | WO | claimed |
| US-20250346575-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-11-13 | — | — | US | disclosed |
| EP-4431505-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2024-09-18 | — | — | EP | disclosed |
| CN-118234721-A | Isoindolinone derivative with glutarimide mother nucleus and application thereof | 韩国化学研究院 | 2024-06-21 | — | — | CN | disclosed |
| CN-111479806-B | D-amino acid oxidase inhibitors and therapeutic uses thereof | 心悦生医股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-31 | — | — | US | disclosed |
| EP-4182310-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-2164329-A2 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | The Burnham Institute for Medical Research (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-06-18 | — | — | US | disclosed |
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-06-18 | — | — | US | disclosed |
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-06-18 | — | — | US | disclosed |
| WO-2009017863-A2 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017863-A2 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20040082079-A1 | Low affinity screening method | GRAFFINITY PHARMACEUTICALS AG. (DE) | 2004-04-29 | — | — | US | disclosed |
| EP-1360489-A1 | LOW AFFINITY SCREENING METHOD | Graffinity Pharmaceuticals Aktiengesellschaft (DE) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002063299-A1 | LOW AFFINITY SCREENING METHOD | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | ALPL, CNDP2, ALPI | ALPL 1/4885CA12 200/4885MARS1 3184/4885 |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ALPL 4166/4885CA12 4119/4885MARS1 4384/4885 |
| US-20250346575-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | CRBN, IDH1, IDH2 | ALPL 3475/4885CA12 3334/4885MARS1 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.